ABSTRACT
Recent studies have shown a relationship between lymphoma and breast implants. We performed a meta-analysis about this problem. We found 80 cases, 50 of which were reported in the United States (62.5%). The average age was 52 years. The average time between breast implant surgery and lymphoma was 11 years. Forty-one percent of the breast implants were silicone, 42.19% were saline and 15.8% were unknown. The coverage of the breast implants was texturized in 21.3% and unknown in 78%. The most common brands were McGhan and Mentor. In 72.6% of the cases, the brand was unknown. The clinical findings were seroma (67.33%), nodes (13.8%), mass (22.1%), other (11.7%) and unknown (32%). The most common surgical treatment was capsulectomy and breast implant removal. In 97% of the cases, ALK was negative and 3% were positive. The most common marker was CD30. The most common chemotherapy regimen was CHOP. Three patients died. Two of the patients had extracapsular extension of the disease and breast cancer history. Lymphoma related with the breast implant was a different type of lymphoma, and in most cases, it was less aggressive. The disease was confined to the capsule. Few patients developed aggressive disease, were extracapsular and showed bad prognosis.
Subject(s)
Breast Implantation/adverse effects , Breast Implants/adverse effects , Breast Neoplasms/surgery , Lymphoma, Large-Cell, Anaplastic/epidemiology , Lymphoma, Large-Cell, Anaplastic/etiology , Anaplastic Lymphoma Kinase , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Biomarkers, Tumor/metabolism , Breast Implantation/methods , Cyclophosphamide/therapeutic use , Doxorubicin/therapeutic use , Female , Humans , Incidence , Lymphoma, Large-Cell, Anaplastic/metabolism , Lymphoma, Large-Cell, Anaplastic/therapy , Mastectomy , Middle Aged , Prednisone/therapeutic use , Receptor Protein-Tyrosine Kinases/metabolism , Risk Factors , Vincristine/therapeutic useABSTRACT
El Linfoma Anaplásico de Células Gigantes (LACG) asociado a implantes mamarios es una patología poco frecuente. Desde el primer caso publicado en la década de los noventa, en los últimos años hemos observado un mayor número de casos recogidos en la literatura. Si bien se tiene información de aproximadamente 90 casos publicados en el mundo, algunos autores mencionan la posibilidad de que existan más de 100 o 200 casos, por lo que su presencia ha suscitado mucha controversia, si bien en general se sigue considerando una patología infrecuente. Hasta donde hemos podido conocer, presentamos el primer caso de LACG documentado por un cirujano plástico en México y América Latina, en una mujer de 43 años de edad portadora de implantes mamarios, con historia de asimetría mamaria unilateral por seroma tardío, y en la que tras 2 punciones sin mejoría de la sintomatología se realizó retirada del implante y capsulectomía, confirmando en líquido periprotésico la presencia del LACG (AU)
Anaplastic Large Cell Lymphoma (ALCL) associated to breast implants is a rare condition. Since the first case report in the nineties, we have seen lately an increase of the total of reported cases. In the literature, we can find around 90 cases and some authors mentioned the possibility of 100 or 200 cases around the world. Anyway it keeps on been and infrequent pathology. To our knowledge, we present the first case reported by a plastic surgeon in Mexico and Latin America in a 43-year female with history of breast augmentation, and unilateral asymmetry due late seroma. After 2 punctures without success, removal of breast implant and capsulectomy was scheduled. Diagnostic of ALCL was confirmed in the periprosthetic fluid (AU)
